Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patients.
Nishida Y, Imamura M, Teraoka Y, Morio K, Fujino H, Ono A, Nakahara T, Murakami E, Yamauchi M, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Abe-Chayama H, Hayes CN, Aikata H, Sasaki N, Sekiguchi T, Kinukawa H, Yoshimura T, Chayama K. Nishida Y, et al. Among authors: teraoka y. J Viral Hepat. 2021 Sep;28(9):1304-1311. doi: 10.1111/jvh.13557. Epub 2021 Jun 20. J Viral Hepat. 2021. PMID: 34105859
Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Kawaoka T, Aikata H, Teraoka Y, Inagaki Y, Honda F, Hatooka M, Morio K, Morio R, Kobayashi T, Nagaoki Y, Nakahara T, Hiramatsu A, Tsuge M, Imamura M, Kawakami Y, Chayama K. Kawaoka T, et al. Among authors: teraoka y. Oncology. 2017;92(6):335-346. doi: 10.1159/000458532. Epub 2017 Mar 1. Oncology. 2017. PMID: 28245484
The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.
Nagaoki Y, Imamura M, Aikata H, Daijo K, Teraoka Y, Honda F, Nakamura Y, Hatooka M, Morio R, Morio K, Kan H, Fujino H, Kobayashi T, Masaki K, Ono A, Nakahara T, Kawaoka T, Tsuge M, Hiramatsu A, Kawakami Y, Hayes CN, Miki D, Ochi H, Chayama K. Nagaoki Y, et al. Among authors: teraoka y. PLoS One. 2017 Aug 10;12(8):e0182710. doi: 10.1371/journal.pone.0182710. eCollection 2017. PLoS One. 2017. PMID: 28797106 Free PMC article.
The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy.
Nagaoki Y, Imamura M, Nishida Y, Daijo K, Teraoka Y, Honda F, Nakamura Y, Morio K, Fujino H, Nakahara T, Kawaoka T, Tsuge M, Hiramatsu A, Kawakami Y, Miki D, Hiyama Y, Ochi H, Chayama K, Aikata H. Nagaoki Y, et al. Among authors: teraoka y. J Med Virol. 2019 Apr;91(4):650-658. doi: 10.1002/jmv.25352. Epub 2018 Nov 19. J Med Virol. 2019. PMID: 30381831
Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma.
Yamauchi M, Ono A, Ishikawa A, Kodama K, Uchikawa S, Hatooka H, Zhang P, Teraoka Y, Morio K, Fujino H, Nakahara T, Murakami E, Miki D, Kawaoka T, Tsuge M, Hiramatsu A, Imamura M, Hayes CN, Fujita M, Nakagawa H, Yasui W, Aikata H, Chayama K. Yamauchi M, et al. Among authors: teraoka y. Clin Transl Gastroenterol. 2020 May;11(5):e00179. doi: 10.14309/ctg.0000000000000179. Clin Transl Gastroenterol. 2020. PMID: 32677805 Free PMC article.
Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study.
Nagaoki Y, Hyogo H, Ando Y, Kosaka Y, Uchikawa S, Nishida Y, Teraoka Y, Morio K, Fujino H, Ono A, Nakahara T, Murakami E, Yamauchi M, Okamoto W, Kawaoka T, Tsuge M, Hiramatsu A, Miki D, Imamura M, Takahashi S, Chayama K, Aikata H. Nagaoki Y, et al. Among authors: teraoka y. BMC Gastroenterol. 2021 Jul 31;21(1):306. doi: 10.1186/s12876-021-01884-5. BMC Gastroenterol. 2021. PMID: 34332532 Free PMC article.
Construction of an anti-hepatitis B virus preS1 antibody and usefulness of preS1 measurement for chronic hepatitis B patients: Anti-HBV PreS1 antibody.
Hatooka H, Shimomura Y, Imamura M, Teraoka Y, Morio K, Fujino H, Ono A, Nakahara T, Murakami E, Yamauchi M, Kawaoka T, Makokha GN, Miki D, Tsuge M, Hiramatsu A, Abe-Chayama H, Hayes CN, Aikata H, Tanaka S, Chayama K. Hatooka H, et al. Among authors: teraoka y. J Infect. 2022 Mar;84(3):391-399. doi: 10.1016/j.jinf.2021.12.025. Epub 2021 Dec 23. J Infect. 2022. PMID: 34953905
126 results